Core Viewpoint - Zhaoyan New Drug (603127) is forecasting a significant increase in net profit for 2025, driven by the appreciation of biological assets, particularly experimental monkeys, despite an expected decline in revenue compared to 2024 [1] Group 1: Financial Performance - The company expects to achieve operating revenue between 1.573 billion to 1.738 billion yuan, a decrease of approximately 13.9% to 22.1% compared to 2024 [1] - Net profit is projected to be between 233 million to 349 million yuan, representing an increase of approximately 214% to 371% from 2024 [1] - The forecasted non-recurring net profit is estimated at 246 million to 370 million yuan, indicating a substantial increase of approximately 945.2% to 1467.7% compared to 2024 [1] Group 2: Asset Valuation and Losses - The market fair value of the company's biological assets is expected to positively impact net profit by approximately 452 million to 499 million yuan due to price increases and natural growth [1] - The laboratory services and other business segments are anticipated to incur losses ranging from 130 million to 206 million yuan [1] Group 3: Market Dynamics - The primary biological asset contributing to the profit increase is experimental monkeys, with price increases expected to occur in the second half of 2025, although specific percentage increases are not yet available [1]